Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia
2014 ASH Annual MeetingKeith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementation of a Heparin-Induced Thrombocytopenia Management Program Reduces the Cost of Diagnostic Testing and Pharmacologic Treatment in an Academic Medical Center,” presented by Caroline Dupre Vaughn, RN.
Related Videos
Laurie Sehn, MD, on Radiotherapy in Limited-Stage Diffuse Large B-Cell Lymphoma
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 393, “R-CHOP With or Without Radiotherapy...
Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379,
Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Labe...
Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes
Richard M. Stone, MD, on the UK NCRI AML17 Trial
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7,
Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibod...
